Commonwealth Equity Services
ABCL icon

Commonwealth Equity Services’s AbCellera Biologics ABCL Stock Holding History

Commonwealth Equity Services’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,757
Closed -$40.2K – 4300
2025
Q4 		$40.2K Sell
11,757
-3,453
-23% -$15.4K ﹤0.01% 4201
2025
Q3 		$77K Sell
15,210
-21,217
-58% -$93.5K ﹤0.01% 4121
2025
Q2 		$125K Buy
+36,427
New +$90.7K ﹤0.01% 4025
2023
Q4 		– Sell
-12,019
Closed -$55K – 3900
2023
Q3 		$55K Buy
12,019
+1,000
+9% +$6.08K ﹤0.01% 3645
2023
Q2 		$71K Sell
11,019
-248
-2% -$1.69K ﹤0.01% 3616
2023
Q1 		$84K Buy
11,267
+722
+7% +$6.56K ﹤0.01% 3521
2022
Q4 		$106K Sell
10,545
-2,600
-20% -$30K ﹤0.01% 3408
2022
Q3 		$130K Sell
13,145
-1,913
-13% -$21K ﹤0.01% 3312
2022
Q2 		$160K Sell
15,058
-481
-3% -$4.07K ﹤0.01% 3271
2022
Q1 		$151K Sell
15,539
-296
-2% -$2.8K ﹤0.01% 3398
2021
Q4 		$226K Sell
15,835
-3,789
-19% -$57.5K ﹤0.01% 3194
2021
Q3 		$393K Buy
+19,624
New +$347K ﹤0.01% 2668

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Commonwealth Equity Services's ABCL Position: Q1 2026 in Review

Commonwealth Equity Services sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 11,757 shares — an estimated $40.2K sold.

Commonwealth Equity Services first reported a position in ABCL in Q3 2021 and held it in 12 quarters. The position peaked at $393K in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Commonwealth Equity Services reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 11,757 AbCellera Biologics shares in Q1 2026, an estimated $40.2K.
  • Commonwealth Equity Services first reported a position in AbCellera Biologics in Q3 2021 and held it in 12 quarters.
  • Commonwealth Equity Services's AbCellera Biologics position peaked at $393K in Q3 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.